Reversibly crosslinked nanocarriers for on-demand drug delivery in cancer treatment
- PMID: 23323559
- PMCID: PMC3575096
- DOI: 10.4155/tde.12.106
Reversibly crosslinked nanocarriers for on-demand drug delivery in cancer treatment
Abstract
Polymer micelles have proven to be one of the most versatile nanocarriers for anticancer drug delivery. However, the in vitro and in vivo stability of micelles remains a challenge due to the dynamic nature of these self-assembled systems, which leads to premature drug release and nonspecific biodistribution in vivo. Recently, reversibly crosslinked micelles have been developed to provide solutions to stabilize nanocarriers in blood circulation. Increased stability allows nanoparticles to accumulate at tumor sites efficiently via passive and/or active tumor targeting, while cleavage of the micelle crosslinkages, through internal or external stimuli, facilitates on-demand drug release. In this review, various crosslinking chemistries as well as the choices for reversible linkages in these nanocarriers will be introduced. Then, the development of reversibly crosslinked micelles for on-demand drug release in response to single or dual stimuli in the tumor microenvironment is discussed, for example, acidic pH, reducing microenvironment, enzymatic microenvironment, photoirradiation and the administration of competitive reagents postmicelle delivery.
Figures





Similar articles
-
Recent Progress of Crosslinking Strategies for Polymeric Micelles with Enhanced Drug Delivery in Cancer Therapy.Curr Med Chem. 2019;26(13):2356-2376. doi: 10.2174/0929867324666171121102255. Curr Med Chem. 2019. PMID: 29165062 Review.
-
Facile construction of bioreducible crosslinked polypeptide micelles for enhanced cancer combination therapy.Acta Biomater. 2017 Nov;63:135-149. doi: 10.1016/j.actbio.2017.09.002. Epub 2017 Sep 7. Acta Biomater. 2017. PMID: 28890258
-
Recent Developments in the Area of Click-Crosslinked Nanocarriers for Drug Delivery.Macromol Rapid Commun. 2019 Feb;40(3):e1800541. doi: 10.1002/marc.201800541. Epub 2018 Nov 12. Macromol Rapid Commun. 2019. PMID: 30417477 Review.
-
Facile construction of dual-bioresponsive biodegradable micelles with superior extracellular stability and activated intracellular drug release.J Control Release. 2015 Jul 28;210:125-33. doi: 10.1016/j.jconrel.2015.05.273. Epub 2015 May 15. J Control Release. 2015. PMID: 25987525
-
[Progress in the study of core-crosslinked polymeric micelles in drug delivery system].Yao Xue Xue Bao. 2014 Feb;49(2):183-9. Yao Xue Xue Bao. 2014. PMID: 24761607 Review. Chinese.
Cited by
-
A structure-property relationship study of the well-defined telodendrimers to improve hemocompatibility of nanocarriers for anticancer drug delivery.Langmuir. 2014 Jun 17;30(23):6878-88. doi: 10.1021/la5003513. Epub 2014 Jun 5. Langmuir. 2014. PMID: 24849780 Free PMC article.
-
Reduction-responsive crosslinked micellar nanoassemblies for tumor-targeted drug delivery.Pharm Res. 2015 Apr;32(4):1325-40. doi: 10.1007/s11095-014-1537-6. Epub 2014 Oct 16. Pharm Res. 2015. PMID: 25319102
-
Photo and redox dual responsive reversibly cross-linked nanocarrier for efficient tumor-targeted drug delivery.ACS Appl Mater Interfaces. 2014 Jul 9;6(13):10381-92. doi: 10.1021/am501913m. Epub 2014 Jun 25. ACS Appl Mater Interfaces. 2014. PMID: 24921150 Free PMC article.
-
A Review on Biomedical Application of Polysaccharide-Based Hydrogels with a Focus on Drug Delivery Systems.Polymers (Basel). 2022 Dec 12;14(24):5432. doi: 10.3390/polym14245432. Polymers (Basel). 2022. PMID: 36559799 Free PMC article. Review.
-
Polyethylene Glycol-Based Polymer-Drug Conjugates: Novel Design and Synthesis Strategies for Enhanced Therapeutic Efficacy and Targeted Drug Delivery.Appl Biochem Biotechnol. 2024 Oct;196(10):7325-7361. doi: 10.1007/s12010-024-04895-6. Epub 2024 Mar 23. Appl Biochem Biotechnol. 2024. PMID: 38519751 Review.
References
-
- Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release. 2000;65(1–2):271–284. - PubMed
-
- Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58–62. [Presented the evidence for vascular abnormalities in tumors, and the therapeutic potential to normalize these vessels for cancer treatment and for the treatment of other diseases characterized by abnormal vessels.] - PubMed
-
- Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 2001;7(9):987–989. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources